Tipifarnib in Treating Patients With Advanced Hematologic Cancer

NCT00005967 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions

DRUG: tipifarnib

Sponsor

National Cancer Institute (NCI)